Stem cell fate decisions: The role of heparan sulfate in the control of autocrine and paracrine signals

Current Stem Cell Research and Therapy

Volumn 3, Issue 1, 2008, Pages 1-8

  Grüenrt, Martin ^a,c   Nucormbe, Victor ^a,b   Cool, Simon M ^a,b  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

BMP; Differentiation; Heparin; Proteoglycan; Stem cell; Wnt

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CHORDIN; FIBROBLAST GROWTH FACTOR; HEPARAN SULFATE; NOGGIN; OSTEOGENIC PROTEIN 1; PROTEOHEPARAN SULFATE; SYNDECAN 4; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; WNT PROTEIN;

AUTOCRINE EFFECT; BONE REMODELING; CARBOHYDRATE ANALYSIS; CELL DIFFERENTIATION; CELL FATE; CELL FUNCTION; CELL LINEAGE; CELL MEMBRANE; CELL SPECIFICITY; EMBRYO PATTERN FORMATION; EMBRYONIC STEM CELL; EXTRACELLULAR MATRIX; HEMATOPOIETIC STEM CELL; HUMAN; IN VIVO STUDY; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; WOUND HEALING;

ANIMALS; AUTOCRINE COMMUNICATION; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; HEPARAN SULFATE PROTEOGLYCANS; HEPARIN; HEPARITIN SULFATE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; PARACRINE COMMUNICATION; PROTEIN BINDING; STEM CELLS; WOUND HEALING;

EID: 47749156869     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488808783489417     Document Type: Review

References (91)

1. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007; 446(7139): 1030-7.
2. Gallagher JT. Multiprotein signalling complexes: regional assembly on heparan sulphate. Biochem Soc Trans 2006; 34(Pt 3): 438-41.
3. Hacker U, Nybakken K, Perrimon Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol 2005; 6(7):530-41.
4. Cool SM, Nurcombe V. Heparan sulfate regulation of progenitor cell fate. J Cell Biochem 2006; 99(4): 1040-51.
5. Nurcombe V, Ford MD, Wildschut A, Bartlett PF. Developmental regulation of neural response to FGF-1 and FGF-2 by heparan sulfate proteoglycan. Science 1993; 260(5104): 103-6.
6. Ornitz DM. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000; 22(2): 108-12.
7. Hardingham TE, Fosang AJ. Proteoglycans: many forms and many functions. FASEB J 1992; 6(3): 861-70.
8. Perrimon N, Bernfield M. Specificities of heparan sulphate proteoglycans in developmental processes. Nature 2000; 404(6779): 725-8.
9. Gallagher JT, Turnbull JE, Lyon M. Patterns of sulphation in heparan sulphate: polymorphism based an a common structural theme. Int J Biochem 1992; 24(4): 553-60.
10. Turnbull JE, Gallagher JT. Heparan sulphate: functional role as a modulator of fibroblast growth factor activity. Biochem Soc Trans 1993; 21(2):477-82.
11. Sanderson RD, Turnbull JE, Gallagher JT, Lander AD. Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. J Biol Chem 1994; 269(18): 13100-6.
12. Merry CL, Wilson VA. Role of heparan sulfate-2-O-sulfotransferase in the mouse. Biochim Biophys Acta 2002; 1573(3):319-27.
13. Esko JD, Zhang L. Influence of core protein sequence on glycosaminoglycan assembly. Curr Opin Struct Biol 1996; 6(5): 663-70.
14. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997; 327 (Pt 1): 1-16.
15. Prydz K, Dalen KT. Synthesis and sorting of proteoglycans. J Cell Sci 2000; 113 Pt 2: 193-205.
16. Vlodavsky I, Goldshmidt O, Zcharia E, et al. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol 2002; 12(2): 121-9.
17. Viviano BL, Paine-Saunders S, Gasiunsis N, Gallagher J, Saunders S. Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist Noggin. J Biol Chem 2004; 279(7):5604-11.
18. Ai X, Do AT, Kusche-Gullberg Lindahl U, Lu K, Emerson CP, Jr. Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2. J Biol Chem 2006; 281(8):4969-76.
19. Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991; 252(5013): 1705-8.
20. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64(4): 841-8.
21. Nakato H, Futch TA, Selleck SB. The division abnormally delayed (dally) gene: a putative integral membrane proteoglycan required for cell division patterning during postembryonic development of the nervous system in Drosophila. Development 1995; 121(11): 3687-702.
22. Galli A, Roure A, Zeller R, Dono R. Glypican 4 modulates FGF signalling and regulates dorsoventral forebrain patterning in Xenopus embryos. Development 2003; 130(20): 4919-29.
23. Topczewski J, Sepich DS, Myers DC, et al. The zebrafish glypican knypek controls cell polarity during gastrulation movements of convergent extension. Dev Cell 2001; 1(2): 251-64.
24. Song HH, Shi W, Xiang YY, Filmus J. The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem 2005; 280(3): 2116-25.
25. Yabe T, Hata T, He J, Maeda N. Developmental and regional expression of heparan sulfate sulfotransferase genes in the mouse brain. Glycobiology 2005; 15(10):982-93.
26. Koziel L, Kunath M, Kelly OG, Vortkamp A. Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Dev Cell 2004; 6(6): 801-13.
27. Shimo T, Gentili C, Iwamoto M, Wu C, Koyama E, Pacifici M. Indian hedgehog and syndecans-3 coregulate chondrocyte proliferation and function during chick limb skeletogenesis. Dev Dyn 2004; 229(3): 607-17.
28. Paine-Saunders S, Viviano BL, Zupicich J, Skarnes WC, Saunders S. glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development Dev Biol 2000; 225(1): 179-87.
29. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, Emerson CP, Jr. Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science 2001; 293(5535): 1663-6.
30. Perrimon N, Bernfield M. Specificities of heparan sulphate proteoglycans in developmental processes. Nature 2000; 404(6779): 725-8.
31. Lander AD. Proteoglycans: master regulators of molecular encounter? Matrix Biol 1998; 17(7): 465-72.
32. Forsten-Williams K, Chua CC, Nugent MA. The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling. J Theor Biol 2005; 233(4): 483-99.
33. Takada T, Katagiri T, Ifuku M, et al. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem 2003; 278(44): 43229-35.
34. Zhao B, Katagiri T, Toyoda H, et al. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem 2006; 281(32): 23246-53.
35. Jeon O, Song SJ, Kang SW, Putnam AJ, Kim BS. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(L-lactic-co-glycolic acid) scaffold. Biomaterials 2007; 28(17): 2763-71.
36. Chang Z, Meyer K, Rapraeger AC, Friedl A. Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ. FASEB J 2000; 14(1): 137-44.
37. Jasuja R, Allen BL, Pappano WN, Rapraeger AC, Greenspan DS. Cell-surface heparan sulfate proteoglycans potentiate chordin antagonism of bone morphogenetic protein signaling and are necessary for cellular uptake of chordin. J Biol Chem 2004; 279(49): 51289-97.
38. Kinsella MG, Irvin C, Reidy MA, Wight TN. Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. Atherosclerosis 2004; 175(1): 51-7.
39. Ling L, Murali S, Dombrowski C, et al. Sulfated glycosaminoglycans mediate the effects of FGF2 on the osteogenic potential of rat calvarial osteoprogenitor cells. J Cell Physiol 2006; 209(3): 811-25.
40. Manton KJ, Sadasivam M, Cool SM, Nurcombe V. Bone-specific heparan sulfates induce osteoblast growth arrest and downregulation of retinoblastoma protein. J Cell Physiol 2006; 209(1): 219-29.
41. Klaassen CD, Boles JW. Sulfation and sulfotransferases 5: the importance of 3′-phosphoadenosine 5′-phosphosulfate (PAPS) in the regulation of sulfation. FASEB J 1997; 11(6): 404-18.
42. Safaiyan F, Kolset SO, Prydz K, Gottfridsson E, Lindahl U, Salmivirta M. Selective effects of sodium chlorate treatment on the sulfation of heparan sulfate. J Biol Chem 1999; 274(51): 36267-73.
43. Guimond SE, Turnbull JE. Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides. Curr Biol 1999; 9(22): 1343-6.
44. McKeehan WL, Wang F, Kan M. The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol 1998; 59: 135-76.
45. Couchman JR, Chen L, Woods A. Syndecans and cell adhesion. Int Rev Cytol 2001; 207: 113-50.
46. Ruoslahti E, Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 1991; 64(5): 867-9.
47. San Antonio JD, Lander AD, Karnovsky MJ, Slayter HS. Mapping the heparin-binding sites on type I collagen monomers and fibrils. J Cell Biol 1994; 125(5): 1179-88.
48. Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 2002; 16(12): 1446-65.
49. Rickard SM, Mummery RS, Mulloy B, Rider CC. The binding of human glial cell line-derived neurotrophic factor to heparin and heparan sulfate: importance of 2-O-sulfate groups and effect on its interaction with its receptor, GFRalpha1. Glycobiology 2003; 13(6): 419-26.
50. Kirkpatrick CA, Knox SM, Staatz WD, Fox B, Lercher DM, Selleck SB. The function of a Drosophila glypican does not depend entirely on heparan sulfate modification. Dev Biol 2006; 300(2): 570-82.
51. Nurcombe V, Smart CE, Chipperfield H, Cool SM, Boilly B, Hondermarck H. The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates. J Biol Chem 2000; 275(39): 30009-18.
52. Chipperfield H, Bedi KS, Cool SM, Nurcombe V. Heparan sulfates isolated from adult neural progenitor cells can direct phenotypic maturation. Int J Dev Biol 2002; 46(4): 661-70.
53. Jackson RA, Murali S, van Wijnen AJ, Stein GS, Nurcombe V, Cool SM. Heparan sulfate regulates the anabolic activity of MC3T3-E1 preosteoblast cells by induction of Runx2. J Cell Physiol 2007; 210(1): 38-50.
54. Ducy P, Starbuck M, Priemel M, et al. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 1999; 13(8): 1025-36.
55. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89(5): 747-54.
56. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89(5): 755-64.
57. Umehara H, Kimura T, Ohtsuka S, et al. Efficient Derivation Of Embryonic Stem Cells By Inhibition Of Glycogen Synthase Kinase-3. Stem Cells 2007.
58. Selleck SB. Shedding light on the distinct functions of proteoglycans. Sci STKE 2006; 2006(329): pe17.
59. Reichsman F, Smith L, Cumberledge S. Glycosaminoglycans can modulate extracellular localization of the wingless protein and promote signal transduction. J Cell Biol 1996; 135(3): 819-27.
60. Uren A, Reichsman F, Anest V, et al. Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. J Biol Chem 2000; 275(6): 4374-82.
61. Zhong X, Desilva T, Lin L, et al. Regulation of Secreted Frizzled-related Protein-1 by Heparin. J Biol Chem 2007; 282(28): 20523-33.
62. Siegfried E, Perrimon N. Drosophila wingless: a paradigm for the function and mechanism of Wnt signaling. Bioessays 1994; 16(6): 395-404.
63. Munoz R, Moreno M, Oliva C, Orbenes C, Larrain J. Syndecan-4 regulates non-canonical Wnt signalling and is essential for convergent and extension movements in Xenopus embryos. Nat Cell Biol 2006; 8(5): 492-500.
64. Urist MR. Bone: formation by autoinduction. Science 1965; 150(698): 893-9.
65. Jones CM, Smith JC. Establishment of a BMP-4 morphogen gradient by long-range inhibition. Dev Biol 1998; 194(1): 12-7.
66. Depprich R, Handschel J, Sebald W, Kubler NR, Wurzler KK. [Comparison of the osteogenic activity of bone morphogenetic protein (BMP) mutants]. Mund Kiefer Gesichtschir 2005; 9(6): 363-8.
67. Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 1996; 237(1): 295-302.
68. Wurzler KK, Emmert J, Eichelsbacher F, Kubler NR, Sebald W, Reuther JF. Evaluation of the osteoinductive potential of genetically modified BMP-2 variants. Mund Kiefer Gesichtschir 2004; 8(2): 83-92.
69. Fisher MC, Li Y, Seghatoleslami MR, Dealy CN, Kosher RA. Heparan sulfate proteoglycans including syndecan-3 modulate BMP activity during limb cartilage differentiation. Matrix Biol 2006; 25(1): 27-39.
70. Jiao X, Billings PC, O'Connell MP, Kaplan FS, Shore EM, Glaser DL. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem 2007; 282(2): 1080-6.
71. Colin S, Jeanny JC, Mascarelli F, et al. In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor. Mol Pharmacol 1999; 55(1): 74-82.
72. Kolset SO, Salmivirta M. Cell surface heparan sulfate proteoglycans and lipoprotein metabolism. Cell Mol Life Sci 1999; 56(9-10): 857-70.
73. Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 2003; 77(24): 13125-35.
74. Irie A, Habuchi H, Kirnata K, Sanai Y. Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochem Biophys Res Commun 2003; 308(4): 858-65.
75. Paine-Saunders S, Viviano BL, Economides AN, Saunders S. Heparan sulfate proteoglycans retain Noggin at the cell surface: a potential mechanism for shaping bone morphogenetic protein gradients. J Biol Chem 2002; 277(3): 2089-96.
76. van der Zee M, Stockhammer O, von Levetzow C, Nunes da Fonseca R, Roth S. Sog/Chordin is required for ventral-to-dorsal Dpp/BMP transport and head formation in a short germ insect. Proc Natl Acad Sci USA 2006; 103(44): 16307-12.
77. Marques G, Musacchio M, Shimell MJ, Wunnenberg-Stapleton K, Cho KW, O'Connor MB. Production of a DPP activity gradient in the early Drosophila embryo through the opposing actions of the SOG and TLD proteins. Cell 1997; 91(3): 417-26.
78. Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 2007; 13(20): 2057-73.
79. Lafont J, Baroukh B, Berdal A, et al. RGTA11, a new healing agent, triggers developmental events during healing of craniotomy defects in adult rats. Growth Factors 1998; 16(1): 23-38.
80. Lafont J, Blanquaert F, Colombier ML, Barritault D, Carueelle JP, Saffar JL. Kinetic study of early regenerative effects of RGTA11, a heparan sulfate mimetic, in rat craniotomy defects. Calcif Tissue Int 2004; 75(6): 517-25.
81. Blanquaert F, Barritault D, Saffar JL, Josefonvicz J, Caruelle JP. CMDBS, functional analogs of sulfate heparanes, used as osseous cicatrizing agents. Ann Endocrinol (Paris) 1994; 55(2): 121-3.
82. Blanquaert F, Saffar JL, Colombier ML, Carpentier G, Barritault D, Caruelle JP. Heparan-like molecules induce the repair of skull defects. Bone 1995; 17(6): 499-506.
83. Blanquaert F, Barritault D, Caruelle JP. Effects of heparan-like polymers associated with growth factors an osteoblast proliferation and phenotype expression. J Biomed Mater Res 1999; 44(1): 63-72.
84. Blanquaert F, Carpentier G, Morvan F, Caruelle JP, Barritault D, Tardieu M. RGTA modulates the healing pattern of a defect in a monolayer of osteoblastic cells by acting on both proliferation and migration. J Biomed Mater Res A 2003; 64(3): 525-32.
85. Jackson RA, McDonald MM, Nurcombe V, Little DG, Cool SM. The use of heparan sulfate to augment fracture repair in a rat fracture model. J Orthop Res 2006; 24(4): 636-44.
86. Luong-Van E, Grondahl L, Nurcombe V, Cool S. In vitro biocompatibility and bioactivity of microencapsulated heparan sulfate. Biomaterials 2007; 28(12): 2127-36.
87. Luong-Van E, Grondahl L, Chua KN, Leong KW, Nurcombe V, Cool SM. Controlled release of heparin from poly(epsilon-caprolactone) electrospun fibers. Biomaterials 2006; 27(9): 2042-50.
88. Badillo AT, Flake AW. The regulatory role of stromal microenvironments in fetal hematopoietic ontogeny. Stem Cell Rev 2006; 2(3): 241-6.
89. Mao L, Wang JQ. Adult neural stem/progenitor cells in neurodegenerative repair. Sheng Li Xue Bao 2003; 55(3): 233-44.
90. Xu RH, Peck RM, Li DS, Feng Y, Ludwig T, Thomson JA. Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation of human ES cells. Nat Methods 2005; 2(3): 185-90.
91. Bendall SC, Stewart MH, Menendez P, et al. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature 2007.